Isabel Castrejon
Overview
Explore the profile of Isabel Castrejon including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
122
Citations
919
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Caponcello M, Navarro P, Bonazzetti C, Campoli C, Savoldi A, Gentilotti E, et al.
Clin Microbiol Infect
. 2025 Mar;
PMID: 40049395
Introduction: The clinical management of COVID-19 in immunocompromised patients remains a challenge. The aim of this work was to develop a consensus to establish recommendations for the clinical, diagnostic and...
2.
Pons M, Georgiadis S, Hetland M, Faizy Ahmadzay Z, Rasmussen S, Christiansen S, et al.
J Rheumatol
. 2025 Feb;
PMID: 39892891
Objective: In patients with axial spondyloarthritis (axSpA) initiating secukinumab (SEC), we aimed to identify baseline (treatment start) predictors of achieving low disease activity (LDA) after 6 months, as measured by...
3.
Ciurea A, Kissling S, Gotschi A, Ornbjerg L, Rasmussen S, Tamasi B, et al.
Arthritis Res Ther
. 2025 Jan;
27(1):18.
PMID: 39891200
Background: Efficacy of tumour necrosis factor inhibitors (TNFi) for peripheral arthritis in patients with psoriatic arthritis (PsA) has been established in randomized clinical trials that have used improvement in summated...
4.
Amar Munoz H, Molina-Collada J, Castrejon I, Monjo-Henry I, Fernandez-Fernandez E, Alvaro-Gracia J, et al.
Clin Exp Rheumatol
. 2024 Dec;
PMID: 39680090
Objectives: To determine if the subtype of vascular ultrasound (US) presentation is associated with different types of ischaemic complications (IC) in giant cell arteritis (GCA). Methods: Retrospective observational analysis of...
5.
Schmukler J, Castrejon I, Li T, Block J, Pincus T
Rheumatol Adv Pract
. 2024 Dec;
8(4):rkae137.
PMID: 39660105
Objective: To analyse interrater reliability of four RheuMetric checklist 0-10 visual numerical scales (VNSs) of physician global assessment (DOCGL), inflammation or reversible findings (DOCINF), organ damage or irreversible findings (DOCDAM)...
6.
Ahmadzay Z, Heberg J, Jorgensen J, Ornbjerg L, Ostergaard M, Moller-Bisgaard S, et al.
Rheumatol Adv Pract
. 2024 Nov;
8(4):rkae135.
PMID: 39611201
Objectives: Real-world evidence is needed to inform treatment strategies for patients with PsA and axial SpA (axSpA) who have non-musculoskeletal manifestations (NMMs), various risk factors and comorbidities. International collaboration is...
7.
Pons M, Georgiadis S, Ostergaard M, Faizy Ahmadzay Z, Glintborg B, Heberg J, et al.
Joint Bone Spine
. 2024 Nov;
92(3):105824.
PMID: 39608666
Objectives: In axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA) patients initiating secukinumab, we aimed to assess retention rates and proportions of patients achieving remission and low disease activity (LDA), according...
8.
Castrejon I, Cano L, Cuadrado M, Borras J, Galindo M, Salman-Monte T, et al.
BMC Rheumatol
. 2024 Oct;
8(1):55.
PMID: 39456098
No abstract available.
9.
Christiansen S, Rasmussen S, Ostergaard M, Pons M, Michelsen B, Pavelka K, et al.
RMD Open
. 2024 Jul;
10(3.
PMID: 39053949
Objectives: To compare the treatment effectiveness of secukinumab in radiographic (r) versus non-radiographic (nr) axial spondyloarthritis (axSpA) patients treated in routine care across Europe. Methods: Prospectively collected data on secukinumab-treated...
10.
Hellamand P, van de Sande M, Nurmohamed M, van Vollenhoven R, Hollick R, Rotariu O, et al.
Rheumatology (Oxford)
. 2024 Jul;
PMID: 39041780
Objectives: To investigate sex differences in patient-reported outcome measures (PROMs) among axSpA patients initiating their first TNFi and identify factors contributing to these disparities over the follow-up. Methods: Data were...